Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Kobashi, M. Abe, K. Mouri, Y. Obase, N. Miyashita, M. Oka (Kurashiki, Japan). Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease. Eur Respir J 2010; 36: Suppl. 54, 3078

Member's Comments

No comment yet.

Related content which might interest you: Treatment outcome of combination antibiotic therapy including clarithromycin for Mycobacterium avium complex pulmonary disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019 Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for Mycobacterium avium complex disease Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Effect of additional drug resistance of M tuberculosis in patients with Hr-TB on the efficacy of chemotherapy Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Lung disease induced by novel chemotherapeutic agents and biomolecules Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002 The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 The effect of combined therapy using rosuvastatin and dihydroarteminin in a pulmonary malaria mouse model. Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury Year: 2018 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 Comparison of anti-tuberculosis regimens using fixed dose combination versus single drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010